Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 30

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1
Chunk 30
---
 manufacture our Hemopurifier.

    ·
    Our Hemopurifier technology may become obsolete.

    ·
    If we fail to comply with extensive regulations of U.S. and foreign regulatory agencies, the commercialization of our products could be delayed or prevented entirely.

    ·
    If we are unable to maintain compliance with the listing requirements of the Nasdaq Capital Market, our common stock may be delisted from the Nasdaq Capital Market, which could have a material adverse effect on our financial condition and could make it more difficult for you to sell your shares.

    ·
    
    As a public company with limited financial resources
    undertaking the launch of new medical technologies, we may have difficulty attracting and retaining executive management and directors.

    ·
    
    We plan to expand our operations, which may strain
    our resources; our inability to manage our growth could delay or derail implementation of our business objectives.

    ·
    
    Our success is dependent in part on our executive
    officers.

    ·
    Delays in successfully commencing or completing our planned clinical trials could jeopardize our ability to obtain regulatory approval and sustain our operations.

 24 

There have been no material changes to the risk factors
previously disclosed under the heading “Risk Factors” in our Annual Report. The risks described in our Annual Report are not
the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial
also may materially adversely affect our business, financial condition or future results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND
USE OF PROCEEDS.

We did not issue or sell any unregistered securities during the three months
ended June 30, 2025.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

Rule 10b5-1 Trading Plans 

During the three months ended June 30, 2025,
none of our directors or officers entered into, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule
10b5-1 trading arrangement,” that were intended to satisfy the affirmative defense conditions of Rule 10b5-1, in each case as defined
in Item 408 of Regulation S-K.

 25 

ITEM 6. EXHIBITS.

(a) Exhibits